{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:36:44Z","timestamp":1787841404238,"version":"build-2784847793"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"DOI":"10.7759\/cureus.115287","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:53:11Z","timestamp":1787838791000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment of Palmoplantar Psoriasis With Bimekizumab Following Secondary Loss of Response to Brodalumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Priyanka","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2016.09.004","article-title":"Palmoplantar psoriasis","volume":"35","author":"Engin B","year":"2017","unstructured":"Engin B, A\u015fk\u0131n \u00d6, T\u00fcz\u00fcn Y. Palmoplantar psoriasis. Clin Dermatol. 2017, 35:19-27. 10.1016\/j.clindermatol.2016.09.004","journal-title":"Clin Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.063","article-title":"Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared\u00a0with moderate to severe plaque psoriasis","volume":"71","author":"Chung J","year":"2014","unstructured":"Chung J, Callis Duffin K, Takeshita J, et al.. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared\u00a0with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014, 71:623-32. 10.1016\/j.jaad.2014.04.063","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1403a191","article-title":"Palmoplantar psoriasis: epidemiological and clinical features and impact on quality of life","volume":"14","author":"Elinkichari D","year":"2024","unstructured":"Elinkichari D, Rabhi F, Jaber K, Dhaoui R. Palmoplantar psoriasis: epidemiological and clinical features and impact on quality of life. Dermatol Pract Concept. 2024, 14:10.5826\/dpc.1403a191","journal-title":"Dermatol Pract Concept"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.1164","article-title":"Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis","volume":"75","author":"Bissonnette R","year":"2016","unstructured":"Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016, 75:99-105. 10.1016\/j.jaad.2016.02.1164","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2026.2637344","article-title":"Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years","volume":"37","author":"Gisondi P","year":"2026","unstructured":"Gisondi P, Elewski B, Pinter A, et al.. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years. J Dermatolog Treat. 2026, 37:2637344. 10.1080\/09546634.2026.2637344","journal-title":"J Dermatolog Treat"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial","volume":"76","author":"Gottlieb A","year":"2017","unstructured":"Gottlieb A, Sullivan J, van Doorn M, et al.. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017, 76:70-80. 10.1016\/j.jaad.2016.07.058","journal-title":"J Am Acad Dermatol"},{"key":"ref7","article-title":"Beyond the usual targets: a case report of overcoming IL-23 and IL-17A biologic nonresponse in palmoplantar psoriasis with brodalumab","volume":"19","author":"Machynia K","year":"2026","unstructured":"Machynia K. Beyond the usual targets: a case report of overcoming IL-23 and IL-17A biologic nonresponse in palmoplantar psoriasis with brodalumab. J Clin Aesthet Dermatol. 2026, 19:10-14.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00746-6","article-title":"Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis","volume":"12","author":"Menter A","year":"2022","unstructured":"Menter A, Bhutani T, Ehst B, Elewski B, Jacobson A. Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis. Dermatol Ther (Heidelb). 2022, 12:1289-302. 10.1007\/s13555-022-00746-6","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42987","article-title":"Multiple biologics treatment failures in patients with psoriasis: a case series of 4 patients","volume":"105","author":"Jensen MB","year":"2025","unstructured":"Jensen MB, Loft N, Zachariae C, Skov L. Multiple biologics treatment failures in patients with psoriasis: a case series of 4 patients. Acta Derm Venereol. 2025, 105:adv42987. 10.2340\/actadv.v105.42987","journal-title":"Acta Derm Venereol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17318","article-title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials","volume":"180","author":"Langley RG","year":"2019","unstructured":"Langley RG, Armstrong AW, Lebwohl MG, et al.. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol. 2019, 180:306-14. 10.1111\/bjd.17318","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.946","article-title":"Twenty patients with moderate to severe psoriasis successfully treated with brodalumab after a failed treatment with secukinumab","volume":"83","author":"Politou M","year":"2020","unstructured":"Politou M, Pompou M, Afroditi KI, Giannoukos A, Nikolaos F. Twenty patients with moderate to severe psoriasis successfully treated with brodalumab after a failed treatment with secukinumab. J Am Acad Dermatol. 2020, 83:214. 10.1016\/j.jaad.2020.06.946","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.043","article-title":"Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials","volume":"89","author":"Spencer RK","year":"2023","unstructured":"Spencer RK, Jin JQ, Elhage KG, Davis MS, Hakimi M, Bhutani T, Liao W. Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials. J Am Acad Dermatol. 2023, 89:423-5. 10.1016\/j.jaad.2023.04.043","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.06.020","article-title":"Effective treatment of recalcitrant palmoplantar psoriasis in a patient with skin of color using bimekizumab","volume":"63","author":"Tocco EG","year":"2025","unstructured":"Tocco EG, Mercante MG, Dasilva DR. Effective treatment of recalcitrant palmoplantar psoriasis in a patient with skin of color using bimekizumab. JAAD Case Rep. 2025, 63:91-2. 10.1016\/j.jdcr.2025.06.020","journal-title":"JAAD Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams R","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al.. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020, 11:1894. 10.3389\/fimmu.2020.01894","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521491-successful-treatment-of-palmoplantar-psoriasis-with-bimekizumab-following-secondary-loss-of-response-to-brodalumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:53:12Z","timestamp":1787838792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521491-successful-treatment-of-palmoplantar-psoriasis-with-bimekizumab-following-secondary-loss-of-response-to-brodalumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.115287","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}